The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback